This landmark 2.3 GW project features Jenbacher-based modular units engineered for fast ramping, high transient response, and ...
Rated at 350 kW, the inverter features six maximum power point trackers (MPPTs) supporting up to 30 module strings. It operates within an MPPT voltage range of 480 V to 1,500 V, with a maximum input ...
Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) ...
This article was produced by Capital & Main. It is published here with permission. Surging electricity demand from data centers across the U.S. is outpacing the supply of new clean energy sources, ...
For seven years, Report on Business magazine has been ranking Canada’s Top Growing Companies. Now, we’re launching two ...
The 2026 World Sportbike Championship will launch under these provisional rules, pending final ratification by the FIM and Dorna WSBK Organisation (DWO). The regulations aim to create an affordable, ...
Texas-based rapid-deployment power specialist VoltaGrid will deploy 2,300 MW of modular, ultra-low-emissions natural gas generation to support Oracle Cloud Infrastructure’s (OCI’s) artificial ...
Level 1, and SPI Analysis - Level 2 Applications introduce new high-speed sniffing capabilities to the Promira Serial Platform for debugging and development of I2C- and SPI-based systems. SUNNYVALE, ...
U.S. truck engine maker Cummins on Thursday reported third-quarter results above Wall Street estimates, driven by strong ...
Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health ...
U.S. electric utility PPL Corp signed agreements to connect 20.5 gigawatts of new data center customers in Pennsylvania to its system by the end of the third financial quarter, a 40% increase from the ...
Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback